These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 7750284)
1. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Fuhrmann U; Slater EP; Fritzemeier KH Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284 [TBL] [Abstract][Full Text] [Related]
2. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878 [TBL] [Abstract][Full Text] [Related]
3. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Kloosterboer HJ; Vonk-Noordegraaf CA; Turpijn EW Contraception; 1988 Sep; 38(3):325-32. PubMed ID: 3139361 [TBL] [Abstract][Full Text] [Related]
4. Binding of a contraceptive progestogen ORG 2969 and its metabolites to receptor proteins and human sex hormone binding globulin. Bergink EW; Hamburger AD; de Jager E; van der Vies J J Steroid Biochem; 1981 Feb; 14(2):175-83. PubMed ID: 6451769 [TBL] [Abstract][Full Text] [Related]
5. Nestorone: a progestin with a unique pharmacological profile. Kumar N; Koide SS; Tsong Y; Sundaram K Steroids; 2000; 65(10-11):629-36. PubMed ID: 11108869 [TBL] [Abstract][Full Text] [Related]
6. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183 [TBL] [Abstract][Full Text] [Related]
7. Contraceptive progestins. Various 11-substituents combined with four 17-substituents: 17alpha-ethynyl, five- and six-membered spiromethylene ethers or six-membered spiromethylene lactones. Schoonen WG; Deckers G; de Gooijer ME; de Ries R; Mathijssen-Mommers G; Hamersma H; Kloosterboer HJ J Steroid Biochem Mol Biol; 2000 Oct; 74(3):109-23. PubMed ID: 11086230 [TBL] [Abstract][Full Text] [Related]
8. Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092 [TBL] [Abstract][Full Text] [Related]
9. Gestodene: a novel synthetic progestin--characterization of binding to receptor and serum proteins. Pollow K; Juchem M; Grill HJ; Elger W; Beier S; Henderson D; Schmidt-Gollwitzer K; Manz B Contraception; 1989 Sep; 40(3):325-41. PubMed ID: 2548807 [TBL] [Abstract][Full Text] [Related]
10. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104 [TBL] [Abstract][Full Text] [Related]
11. Characteristics of the new progestogens in combination oral contraceptives. Rebar RW; Zeserson K Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625 [TBL] [Abstract][Full Text] [Related]
12. Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Juchem M; Pollow K Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2171-83. PubMed ID: 2175153 [TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Phillips A; Hahn DW; McGuire JL Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445 [TBL] [Abstract][Full Text] [Related]
14. Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives. Collins DC Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1508-13. PubMed ID: 8178899 [TBL] [Abstract][Full Text] [Related]
15. The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. Lemus AE; Zaga V; Santillán R; García GA; Grillasca I; Damián-Matsumura P; Jackson KJ; Cooney AJ; Larrea F; Pérez-Palacios G J Endocrinol; 2000 Jun; 165(3):693-702. PubMed ID: 10828854 [TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of trimegestone: a new potent and selective progestin. Zhang Z; Lundeen SG; Zhu Y; Carver JM; Winneker RC Steroids; 2000; 65(10-11):637-43. PubMed ID: 11108870 [TBL] [Abstract][Full Text] [Related]
17. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum. Kuhnz W; Pfeffer M; al-Yacoub G J Steroid Biochem; 1990 Feb; 35(2):313-8. PubMed ID: 2308344 [TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacology of newer progestogens. Kuhl H Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163 [TBL] [Abstract][Full Text] [Related]
19. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317 [TBL] [Abstract][Full Text] [Related]
20. Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals. Deckers GH; Schoonen WG; Kloosterboer HJ J Steroid Biochem Mol Biol; 2000 Oct; 74(3):83-92. PubMed ID: 11086227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]